LumaVida Women’s Health Institute Business Plan — Debt Service, Cover Ratios & Returns

This section assesses the plan from the perspectives that matter most to lenders and equity investors: debt-service cover, capital efficiency, and risk-adjusted returns, with the clinic rollout ramp as the central sensitivity and a clear-eyed treatment of why the returns are high and where the risks lie.

Debt-service cover and capital efficiency

Metric	Year 1	Year 2	Year 3	Year 4	Year 5
CFADS	3	11	17	25	33
Debt service	0	1	3	18	21
DSCR (x)	n/a	8.83x	5.25x	1.38x	1.55x
Net debt / EBITDA (x)	-2.28x	-1.08x	-0.98x	-0.27x	-0.13x
ROCE	4.3%	6.6%	8.2%	13.4%	19.0%

Figure 28. *Debt profile and debt-service cover ratio*

StrengthDebt is comfortably serviced — unlike a heavy-capital rollout

Because the network is profitable from Year 1 and carries only modest debt, debt-service cover is comfortable from the point debt is drawn, there is no early-year cover gap of the kind a theatre-owning surgical rollout would face. This is the flip side of the capital-light model: less capital to deploy, but also far less financial risk during the build. The conservative leverage (net cash by Year 5) leaves ample headroom for the Phase-2 development facility.

Returns — strong, and why

On the sponsor’s targets, revenue of ~R180 million and a ~25% EBITDA margin, exited at a conservative 9x EV/EBITDA on Year-5 EBITDA of ~R45 million, the plan delivers a project IRR near 83%, an equity IRR of about 66%, and a money multiple around 4.8x. These returns are strong, and they are so for a specific structural reason: the business is capital-light. A modest capital base supports a business generating ~R45 million of EBITDA by Year 5, valued at over R400 million at exit. The returns are real arithmetic, but they are a ceiling contingent on delivering the rollout, the membership and, above all, the staffing.

Rollout ramp vs plan	80%	90%	100%	110%	120%
Equity IRR	55%	61%	66%	71%	76%

Figure 30. *Equity IRR sensitivity to the rollout ramp*

Analyst flagRead the returns as a ceiling — and underwrite the staffing and the follow-on

Three honest caveats attach to the headline returns. First, they assume nine clinics are built, staffed, filled and the Phase-2 raise secured; a combined-stress scenario, a 20% weaker ramp, a 15% lower margin and a 7x exit, still returns roughly 37%, cushioned by the light capital base, but that resilience is a feature of the small equity cheque, not evidence the base case is safe. Second, the returns are gated by specialist supply: if the OB/GYN and fertility roles cannot be filled, the revenue, and every return figure, does not materialise. Third, the 10,000-member target is ambitious and must be validated. Investors should underwrite the recruitment, membership and follow-on-funding plans, not the headline IRR.

Figure 31. *Equity IRR sensitivity to key drivers (tornado)*

Three-case scenario analysis

Framing the decision as three underwriteable cases is more honest than a single headline. The combined-stress case, a 20% weaker ramp, a 15% lower margin and a 7x exit, returns roughly 37%; the base case (the sponsor targets at 9x) returns about 66%; the upside case (a stronger ramp at a premium multiple) is higher still. Every case clears the 18% cost of equity comfortably, on a capital base this light, the question is not whether the equity is in the money but whether the base case can be delivered, which turns on staffing and the follow-on raise.

	Combined stress	Base	Upside
Scenario	Ramp –20%, margin –15%, 7x	Sponsor targets, 9x	Ramp +20%, 13x
Equity IRR	37%	66%	96%
Assessment	Still above hurdle	Ceiling case	Exceptional

Figure 32. *Equity IRR — base, upside and a combined stress*

Two-dimensional sensitivity — rollout ramp and exit multiple

The two variables that most drive the equity return are the rollout ramp (which sets the mature EBITDA) and the exit multiple (which capitalises it). The grid below shows equity IRR across both simultaneously.

Ramp \\ Exit x	7.0x	9.0x	11.0x	13.0x
80% ramp	44%	55%	65%	74%
90% ramp	49%	61%	71%	80%
100% ramp	54%	66%	76%	86%
110% ramp	58%	71%	82%	91%
120% ramp	63%	76%	86%	96%

Even in the bottom-left corner, a weak ramp exited at 7x, the return remains above the cost of equity, because the capital base is so light. The variable not on this grid, whether the OB/GYN and fertility roles can be filled across nine provinces, is the one that most determines whether any of these outcomes is achieved.

Indicative covenant package

Covenant / structural feature	Indicative level	Rationale
Minimum DSCR	≥ 1.30x from Year 2	Applies once debt is drawn & clinics contribute
Phase-2 funding condition	Follow-on committed pre-expansion	National rollout depends on it
Working-capital facility	Committed, sized to receivables	Funds medical-aid receivable book
Principal grace period	Through the early rollout	Matches the build to cash generation
Staffing / opening covenant	Monitored vs plan	Early-warning on the binding constraints
Dividend lock-up	Until cover & leverage tests met	Retains cash through the rollout

Valuation and exit

The base case applies a conservative 9x EV/EBITDA exit multiple to Year-5 EBITDA of about R45 million, implying an enterprise value around R405 million and equity value of roughly R411 million after net cash. A 9x multiple is restrained for a growing, branded, integrated women’s-health platform with recurring membership revenue. Four credible exit routes support liquidity: a trade sale to a private-hospital or healthcare group seeking a women’s-health platform, a healthcare-investment-fund or private-equity secondary, an international women’s-health-platform acquisition, or a long-term hold generating strong dividends. The scarcity value of a built, staffed, national women’s-health brand, precisely because it is so hard to assemble, is what a strategic acquirer would pay for.

Exit metric	Value
Year-5 EBITDA	~R45m
Exit multiple (EV/EBITDA)	9.0x
Implied enterprise value	~R405m
Implied equity value (net of cash)	~R411m
Project IRR / equity IRR	~83% / ~66%
Money multiple (MOIC)	~4.8x (a ceiling)

Financing process and next steps

Seed close of R25m to fund the Johannesburg flagship and the digital platform, proof-of-concept for the model.
Specialist-recruitment due diligence — a credible plan to recruit and retain OB/GYNs and fertility subspecialists, the single most important condition precedent.
Phase-2 follow-on structuring of the ~R95m of additional equity and development finance, staged and milestone-linked to clinic openings.
Hospital & medical-aid contracting — partnership agreements for deliveries and surgery, and medical-aid network agreements, to validate the model and the ramp.